Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity
Highlights
- Dupilumab led to higher complete response rates and fewer discontinuations of cancer therapy compared to systemic steroids for ADC-induced dermatologic adverse events.
- Patients receiving dupilumab showed rapid improvement, with a median time to first clinical response of 24 days.
- No patients in the dupilumab group discontinued cancer therapy due to skin toxicities, compared to 43.8% in the steroid group.
- Dupilumab offers a promising steroid-sparing approach for managing challenging cutaneous reactions in cancer patients on ADCs.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.